The Health Department has
issued new information on
infliximab, which was formally
listed on the PBS effective from
yesterday as a biosimilar for the
same indications as Remicade.
Fact sheets for patients as well
as healthcare professionals are
featured, detailing applicable
conditions including Crohn’s
disease, rheumatoid arthritis and
ankylosing spondylitis.
Infliximab is a highly specialised
(S100) drug which must be
prescribed by specialists - pbs.gov.au.The above article was sent to subscribers in Pharmacy Daily's issue from 02 Dec 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 Dec 15
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.